AGL

Agilon Health, Inc. (AGL) executed a 25-to-1 reverse stock split on March 31, 2026. In July 2026, the stock dropped by 10.8% after a downgrade from Citi, which cited valuation concerns following a significant 650% rally in 2026. This downgrade coincided with news of a law firm investigating the company for potential false statements about its medical costs. Despite reporting strong second-quarter 2026 results in August 2026, with $1.49 billion in revenue and a significant increase in adjusted EBITDA, and raising its full-year 2026 guidance, the stock fell by approximately 20%. As of September 25, 2026, the stock price was $80.73 per share, representing a 190.92% increase from September 29, 2025 (not adjusted for the reverse split). The 52-week high was $133.04, and the 52-week low was $7.48.